Triple hormone receptor agonist retatrutide for metabolic
2024年6月10日 · Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight...
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A …
2023年6月26日 · Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side...
Therapeutic landscape of metabolic dysfunction-associated ...
2024年11月28日 · Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic dysfunction-associated steatohepatitis (MASH) have become a global...
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight...
Lilly's phase 2 retatrutide results published in The New England ...
2023年6月26日 · In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg) ii at the end of the 48-week treatment duration. The results were presented in a symposium at the American Diabetes Association's ® 83rd Scientific Sessions and were simultaneously published in The New England Journal of Medicine (NEJM) .
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A …
2023年8月10日 · Background: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for …
2023年6月26日 · Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic poly-peptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relation-ships with respect to side...
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
2023年10月25日 · To the Editor: Jastreboff and colleagues (Aug. 10 issue) 1,2 describe the results of their phase 2 trial of retatrutide, an agonist of three G-protein–coupled receptors, which led to marked...
What is the pipeline for future medications for obesity?
2024年2月1日 · In people with T2D, retatrutide (0.5 to 12 mg) led to substantial reductions in bodyweight and HbA1c compared to both placebo and dulaglutide 1.5 mg in a phase 2 trial .
Review of current and new drugs for the treatment of metabolic ...
2024年6月8日 · Retatrutide is a triple receptor agonist targeting GLP-1, glucagon, and GIP receptors. Jastreboff and colleagues noted that higher doses of retatrutide resulted in a reduction of multiple risk factors for MAFLD, such as waist circumference, systolic and diastolic blood pressure, and levels of serum glycated hemoglobin, fasting glucose, and ...